Usefulness of [18F]fluoro-2-deoxy-D-glucose positron emission tomography for predicting the World Health Organization malignancy grade of thymic epithelial tumors

被引:25
作者
Igai, Hitoshi [1 ]
Matsuura, Natsumi [1 ]
Tarumi, Shintaro [1 ]
Chang, Sung Soo [1 ]
Misaki, Noriyuki [1 ]
Go, Tetsuhiko [1 ]
Ishikawa, Shinya [1 ]
Yokomise, Hiroyasu [1 ]
机构
[1] Kagawa Univ, Dept Gen Thorac Surg Breast & Endocrinol Surg, Kagawa, Japan
关键词
(18)FDG-PET; WHO classification; Thymic epithelial tumors; CLASSIFICATION;
D O I
10.1016/j.ejcts.2010.09.009
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to investigate whether the maximum standardized uptake value (SUVmax) determined using positron emission tomography with [F-18] fluoro-2-deoxy-D-glucose ((18)FDG-PET) can predict the grade of malignancy of thymic epithelial tumors based on the World Health Organization (WHO) classification. Methods: We retrospectively analyzed 13 patients with thymic epithelial tumors, who underwent (18)FDG-PET examination before treatment. The patients were subdivided into a thymoma group and a thymic carcinoma group, and the two were compared clinicopathologically. Results: There were six men and seven women, ranging in age from 36 to 78 years (mean, 58.8 +/- 13.3 years). Mean tumor size was 47.3 +/- 26.0 mm, and the WHO classification was type A in two patients, type AB in none, type B1 in one, type B2 in three, type B3 in two, and thymic carcinoma in five. Thus, eight patients had thymoma and five had thymic carcinoma. The Masaoka stage was I in four patients, II in four, III in three, and IV in two. Mean pre-treatment SUVmax for the tumors overall was 5.24 +/- 3.10, with a range of 1.73-11.21. Mean SUVmax in the thymic carcinoma group was 8.15 +/- 7.88, and that in the thymoma group was 3.43 +/- 2.19, the difference being significant (P = 0.002). Conclusions: A significant relationship was observed between SUVmax and morphological classification by the WHO system for this cohort of thymic epithelial tumors. Pre-treatment SUVmax may be useful for differentiating thymoma from thymic carcinoma. (C) 2010 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
引用
收藏
页码:143 / 145
页数:3
相关论文
共 15 条
[1]  
Ahuja V, 1998, CANCER, V83, P918, DOI 10.1002/(SICI)1097-0142(19980901)83:5<918::AID-CNCR17>3.3.CO
[2]  
2-#
[3]  
[Anonymous], 2004, Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs
[4]   LUNG-TUMOR GROWTH CORRELATES WITH GLUCOSE-METABOLISM MEASURED BY FLUORIDE-18 FLUORODEOXYGLUCOSE POSITRON EMISSION TOMOGRAPHY [J].
DUHAYLONGSOD, FG ;
LOWE, VJ ;
PATZ, EF ;
VAUGHN, AL ;
COLEMAN, E ;
WOLFE, WG .
ANNALS OF THORACIC SURGERY, 1995, 60 (05) :1348-1352
[5]   Utility of 18FDG-PET for differentiating the grade of malignancy in thymic epithelial tumors [J].
Endo, Masahiro ;
Nakagawa, Kazuo ;
Ohde, Yasuhisa ;
Okumura, Takehiro ;
Kondo, Haruhiko ;
Igawa, Satoshi ;
Nakamura, Yukiko ;
Tsuya, Asuka ;
Murakami, Haruyasu ;
Takahashi, Toshiaki ;
Yamamoto, Nobuyuki ;
Ito, Ichiro ;
Kameya, Toru .
LUNG CANCER, 2008, 61 (03) :350-355
[6]   18F-FDG PET for the evaluation of thymic epithelial tumors: Correlation with the World Health Organization classification in addition to dual-time-point imaging [J].
Inoue, Atsuo ;
Tomiyama, Noriyuki ;
Tatsumi, Mitsuaki ;
Ikeda, Naoki ;
Okumura, Meinoshin ;
Shiono, Hiroyuki ;
Inoue, Masayoshi ;
Higuchi, Ichiro ;
Aozasa, Katsuyuki ;
Johkoh, Takeshi ;
Nakamura, Hironobu ;
Hatazawa, Jun .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2009, 36 (08) :1219-1225
[7]   WHO histologic classification is a prognostic indicator in thymoma [J].
Kondo, K ;
Yoshizawa, K ;
Tsuyuguchi, M ;
Kimura, S ;
Sumitomo, M ;
Morita, J ;
Miyoshi, T ;
Sakiyama, S ;
Mukai, K ;
Monden, Y .
ANNALS OF THORACIC SURGERY, 2004, 77 (04) :1183-1188
[8]   Characterization of thymic masses using 18F-FDG PET-CT [J].
Kumar, Arvind ;
Regmi, Subodh Kumar ;
Dutta, Roman ;
Kumar, Rakesh ;
Gupta, Siddhartha Datta ;
Das, Prasenjit ;
Halanaik, Dhanapathi ;
Jindal, Tarun .
ANNALS OF NUCLEAR MEDICINE, 2009, 23 (06) :569-577
[9]  
LINDHOLM P, 1993, J NUCL MED, V34, P1
[10]  
Nakata B, 1997, CANCER, V79, P695, DOI 10.1002/(SICI)1097-0142(19970215)79:4<695::AID-CNCR6>3.3.CO